Treating nausea and vomiting in palliative care: A review

Clinical Interventions in Aging

Volumn 6, Issue 1, 2011, Pages 243-259

  Glare, Paul ^a   Miller, Jeanna ^a   Nikolova, Tanya ^a   Tickoo, Roma ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

Nausea; Palliative care; Vomiting

Indexed keywords

ANTIHISTAMINIC AGENT; BENZODIAZEPINE DERIVATIVE; CANNABINOID; CHLORPROMAZINE; CORTICOSTEROID; DEXAMETHASONE; DOLASETRON MESILATE; DOPAMINE RECEPTOR BLOCKING AGENT; ERYTHROMYCIN; GRANISETRON; HALOPERIDOL; INSULIN; LEVOMEPROMAZINE; METOCLOPRAMIDE; OCTREOTIDE; OLANZAPINE; ONDANSETRON; PALONOSETRON; PHENOTHIAZINE DERIVATIVE; PIPERAZINE; PLACEBO; PROCHLORPERAZINE; PROKINETIC AGENT; PROMETHAZINE; SCOPOLAMINE; SCOPOLAMINE BROMIDE; SCOPOLAMINE BUTYL BROMIDE; SEROTONIN 3 ANTAGONIST; TRAMADOL; UNINDEXED DRUG;

ABDOMINAL CRAMP; ANTICHOLINERGIC EFFECT; ANXIETY DISORDER; AVOIDANCE BEHAVIOR; BEDTIME DOSAGE; BEHAVIOR THERAPY; BRADYCARDIA; CANCER ASSOCIATED DYSPEPSIA SYNDROME; CARDIOTOXICITY; CHEMOTHERAPY INDUCED EMESIS; CLINICAL FEATURE; COMORBIDITY; CONFUSION; CONSTIPATION; CONTINUOUS INFUSION; CREATININE CLEARANCE; DEMENTIA; DIARRHEA; DISEASE ASSOCIATION; DISEASE CONTROL; DIZZINESS; DROWSINESS; DRUG ANTAGONISM; DRUG BIOAVAILABILITY; DRUG DOSE REDUCTION; DRUG DOSE TITRATION; DRUG FEVER; DRUG HALF LIFE; DRUG INDUCED HEADACHE; DRUG MECHANISM; DRUG MEGADOSE; DRUG TOXICITY; DRUG WITHDRAWAL; DYSPEPSIA; DYSTONIA; EDEMA; EXTRAPYRAMIDAL SYMPTOM; FATIGUE; GALLSTONE; GASTROINTESTINAL DISEASE; GASTROINTESTINAL SYMPTOM; GERIATRIC PATIENT; HALLUCINATION; HEART RATE; HUMAN; HYPERGLYCEMIA; HYPOTENSION; HYPOTHYROIDISM; INCREASED APPETITE; INJECTION SITE BURNING; INJECTION SITE PAIN; INJECTION SITE STINGING; INTESTINE OBSTRUCTION; INTRACRANIAL HYPERTENSION; KIDNEY FAILURE; LEUKOCYTE COUNT; LIVER FUNCTION; MOTION SICKNESS; NAUSEA; NAUSEA AND VOMITING; NEUTROPENIA; ORTHOSTATIC HYPOTENSION; PALLIATIVE THERAPY; PATIENT ASSESSMENT; PERCUTANEOUS ENDOSCOPIC GASTROSTOMY; POSTOPERATIVE NAUSEA AND VOMITING; PREVALENCE; QT INTERVAL; QT PROLONGATION; RESPIRATION DEPRESSION; RESTLESSNESS; REVIEW; SEDATION; SEIZURE; SEIZURE THRESHOLD; SEPSIS; SIDE EFFECT; SKIN MANIFESTATION; SOMNOLENCE; TIME TO MAXIMUM PLASMA CONCENTRATION; URINE RETENTION; VESTIBULAR DISORDER; VOMITING; WEIGHT GAIN; XEROSTOMIA;

EID: 80755143270     PISSN: 11769092     EISSN: 11781998     Source Type: Journal    
DOI: 10.2147/cia.s13109     Document Type: Review

References (165)

1. Baines MJ. ABC of palliative care. Nausea, vomiting, and intestinal obstruction. BMJ. 1997;315(7116):1148-1150.
2. Peroutka SJ, Snyder SH. Antiemetics: neurotransmitter receptor binding predicts therapeutic actions. Lancet. 1982;1(8273):658-659.
3. Grunberg SM, Hesketh PJ. Control of chemotherapy-induced emesis. N Engl J Med. 1993;329(24):1790-1796.
4. Steadman K, Franks A. A woman with malignant bowel obstruction who did not want to die with tubes. Lancet. 1996;347(9006):944.
5. Cleeland CS, Bennett GJ, Dantzer R, et al. Are the symptoms of cancer and cancer treatment due to a shared biologic mechanism? A cytokineimmunologic model of cancer symptoms. Cancer. 2003;97(11):2919-2925.
6. Bishop TF, Morrison RS. Geriatric palliative care-Part I: pain and symptom management. Clin Geriatr. 2007;15(1):25-32.
7. Sutton LM, Demark-Wahnefried W, Clipp EC. Management of terminal cancer in elderly patients. Lancet Oncol. 2003;4(3):149-157.
8. Feuer DJ, Broadley KE. Corticosteroids for the resolution of malignant bowel obstruction in advanced gynaecological and gastrointestinal cancer. Cochrane Database Syst Rev. 2000;3:CD001219.
9. Barford KL, D'Olimpio JT. Symptom management in geriatric oncology: practical treatment considerations and current challenges. Curr Treat Options Oncol. 2008;9(2-3):204-214.
10. Solano JP, Gomes B, Higginson IJ. A comparison of symptom prevalence in far advanced cancer, AIDS, heart disease, chronic obstructive pulmonary disease and renal disease. J Pain Symptom Manage. 2006;31(1):58-69.
11. Stephenson J, Davies A. An assessment of aetiology-based guidelines for the management of nausea and vomiting in patients with advanced cancer. Support Care Cancer. 2006;14(4):348-353.
12. Bruera E, Kuehn N, Miller MJ, Selmser P, Macmillan K. The Edmonton Symptom Assessment System (ESAS): a simple method for the assessment of palliative care patients. J Palliat Care. 1991;7(2):6-9.
13. Portenoy RK, Thaler HT, Kornblith AB, et al. The memorial symptom assessment scale: an instrument for the evaluation of symptom prevalence, characteristics and distress. Eur J Cancer. 1994;30A(9):1326-1336.
14. Melzack R, Rosberger Z, Hollingsworth ML, Thirlwell M. New approaches to measuring nausea. CMAJ. 1985;133(8):755-758.
15. Sigurdardottir KR, Haugen DF. Prevalence of distressing symptoms in hospitalised patients on medical wards: a cross-sectional study. BMC Palliat Care. 2008;7:16.
16. Seow H, Barbera L, Sutradhar R, et al. Trajectory of performance status and symptom scores for patients with cancer during the last six months of life. J Clin Oncol. 2011;29(9):1151-1158.
17. Yates P. Clinical and patient perspectives on factors contributing to nausea in advanced cancer. Oncol Nurs Forum. 2006;33(2):468-469.
18. Chang VT, Hwang SS, Kasimis B, Thaler HT. Shorter symptom assessment instruments: the Condensed Memorial Symptom Assessment Scale (CMSAS). Cancer Invest. 2004;22(4):526-536.
19. Ventafridda V, De Conno F, Ripamonti C, Gamba A, Tamburini M. Quality-of-life assessment during a palliative care programme. Ann Oncol. 1990;1(6):415-420.
20. Donnelly S, Walsh D, Rybicki L. The symptoms of advanced cancer: identification of clinical and research priorities by assessment of prevalence and severity. J Palliat Care. 1995;11(1):27-32.
21. Vainio A, Auvinen A. Prevalence of symptoms among patients with advanced cancer: an international collaborative study. Symptom Prevalence Group. J Pain Symptom Manage. 1996;12(1):3-10.
22. Reuben DB, Mor V. Nausea and vomiting in terminal cancer patients. Arch Intern Med. 1986;146(10):2021-2023.
23. Coyle N, Adelhardt J, Foley KM, Portenoy RK. Character of terminal illness in the advanced cancer patient: pain and other symptoms during the last four weeks of life. J Pain Symptom Manage. 1990;5(2):83-93.
24. Fainsinger R, Miller MJ, Bruera E, Hanson J, Maceachern T. Symptom control during the last week of life on a palliative care unit. J Palliat Care. 1991;7(1):5-11.
25. Conill C, Verger E, Henriquez I, et al. Symptom prevalence in the last week of life. J Pain Symptom Manage. 1997;14(6):328-331.
26. Mercadante S, Casuccio A, Fulfaro F. The course of symptom frequency and intensity in advanced cancer patients followed at home. J Pain Symptom Manage. 2000;20(2):104-112.
27. Bruera E, Neumann C, Brenneis C, Quan H. Frequency of symptom distress and poor prognostic indicators in palliative cancer patients admitted to a tertiary palliative care unit, hospices, and acute care hospitals. J Palliat Care. 2000;16(3):16-21.
28. Reuben D. Nausea and vomiting in terminal cancer patients. Arch Intern Med. 1986;146(10):2021-2023.
29. Greaves J, Glare P, Kristjanson LJ, Stockler M, Tattersall MH. Undertreatment of nausea and other symptoms in hospitalized cancer patients. Support Care Cancer. 2009;17(4):461-464.
30. Cheung WY, Le LW, Zimmermann C. Symptom clusters in patients with advanced cancers. Support Care Cancer. 2009;17(9):1223-1230.
31. Quigley EM, Hasler WL, Parkman HP. AGA technical review on nausea and vomiting. Gastroenterology. 2001;120(1):263-286.
32. Meineche-Schmidt V, Christensen E. Classification of dyspepsia. Identification of independent symptom components in 7270 consecutive, unselected dyspepsia patients from general practice. Scand J Gastroenterol. 1998;33(12):1262-1272.
33. Talley NJ, Phillips SF. Non-ulcer dyspepsia: potential causes and pathophysiology. Ann Intern Med. 1988;108(6):865-879.
34. Bruera E, Belzile M, Neumann C, Harsanyi Z, Babul N, Darke A. A double-blind, crossover study of controlled-release metoclopramide and placebo for the chronic nausea and dyspepsia of advanced cancer. J Pain Symptom Manage. 2000;19(6):427-435.
35. American Gastroenterological Association. Medical position statement: nausea and vomiting. Gastroenterology. 2001;120(1):261-263.
36. Gan TJ, Meyer T, Apfel CC, et al. Consensus guidelines for managing postoperative nausea and vomiting. Anesth Analg. 2003;97(1):62-71.
37. Jordan K, Sippel C, Schmoll HJ. Guidelines for antiemetic treatment of chemotherapy-induced nausea and vomiting: past, present, and future recommendations. Oncologist. 2007;12(9):1143-1150.
38. Lichter I. Nausea and vomiting in patients with cancer. Hematol Oncol Clin North Am. 1996;10(1):207-220.
39. Bentley A, Boyd K. Use of clinical pictures in the management of nausea and vomiting: a prospective audit. Palliat Med. 2001;15(3):247-253.
40. Walsh D, Donnelly S, Rybicki L. The symptoms of advanced cancer: relationship to age, gender, and performance status in 1,000 patients. Support Care Cancer. 2000;8(3):175-179.
41. Morita T, Tsunoda J, Inoue S, Chihara S. Contributing factors to physical symptoms in terminally-ill cancer patients. J Pain Symptom Manage. 1999;18(5):338-346.
42. Mercadante S, Fulfaro F, Casuccio A. The impact of home palliative care on symptoms in advanced cancer patients. Support Care Cancer. 2000;8(4):307-310.
43. Meuser T, Pietruck C, Radbruch L, Stute P, Lehmann KA, Grond S. Symptoms during cancer pain treatment following WHO guidelines: a longitudinal follow-up study of symptom prevalence, severity and etiology. Pain. 2001;93(3):247-257.
44. Turner J, Zapart S, Pedersen K, Rankin N, Luxford K, Fletcher J. Clinical practice guidelines for the psychosocial care of adults with cancer. Psychooncology. 2005;14(3):159-173.
45. Hesketh PJ. Chemotherapy-induced nausea and vomiting. N Engl J Med. 2008;358(23):2482-2494.
46. Lichter I. Results of antiemetic management in terminal illness. J Palliat Care. 1993;9(2):19-21.
47. Bruera ED, MacEachern TJ, Spachynski KA, et al. Comparison of the efficacy, safety, and pharmacokinetics of controlled release and immediate release metoclopramide for the management of chronic nausea in patients with advanced cancer. Cancer. 1994;74(12):3204-3211.
48. Bruera E, Seifert L, Watanabe S, et al. Chronic nausea in advanced cancer patients: a retrospective assessment of a metoclopramide-based antiemetic regimen. J Pain Symptom Manage. 1996;11(3):147-153.
49. Mystakidou K, Befon S, Liossi C, Vlachos L. Comparison of the efficacy and safety of tropisetron, metoclopramide, and chlorpromazine in the treatment of emesis associated with far advanced cancer. Cancer. 1998;83(6):1214-1223.
50. Perkins P, Dorman S. Haloperidol for the treatment of nausea and vomiting in palliative care patients. Cochrane Database Syst Rev. 2009;2:CD006271.
51. Ezzo JM, Richardson MA, Vickers A, et al. Acupuncture-point stimulation for chemotherapy-induced nausea or vomiting. Cochrane Database Syst Rev. 2006;2:CD002285.
52. Clark K, Agar MR, Currow D. Metoclopramide for chronic nausea in adult palliative care patients with advanced cancer (Protocol). Cochrane Database Syst Rev. 2010(2).
53. Walkembach J, Bruss M, Urban BW, Barann M. Interactions of metoclopramide and ergotamine with human 5-HT(3 A) receptors and human 5-HT reuptake carriers. Br J Pharmacol. 2005;146(4):543-552.
54. De Maeyer JH, Lefebvre RA, Schuurkes JA. 5-HT4 receptor agonists: similar but not the same. Neurogastroenterol Motil. 2008;20(2):99-112.
55. Cuomo R, Vandaele P, Coulie B, et al. Influence of motilin on gastric fundus tone and on meal-induced satiety in man: role of cholinergic pathways. Am J Gastroenterol. 2006;101(4):804-811.
56. Schuurkes JAJ, Helsen LFM, Ghoos ECR, Eelen JGMG, van Nueten JM. Stimulation of gastroduodenal motor activity: dopaminergic and cholinergic modulation. Drug Dev Res. 1986;8(1-4):233-241.
57. Magueur E, Hagege H, Attali P, Singlas E, Etienne JP, Taburet AM. Pharmacokinetics of metoclopramide in patients with liver cirrhosis. Br J Clin Pharmacol. 1991;31(2):185-187.
58. Bateman DN, Gokal R, Dodd TR, Blain PG. The pharmacokinetics of single doses of metoclopramide in renal failure. Eur J Clin Pharmacol. 1981;19(6):437-441.
59. Santucci G, Mack JW. Common gastrointestinal symptoms in pediatric palliative care: nausea, vomiting, constipation, anorexia, cachexia. Pediatr Clin North Am. 2007;54(5):673-689.
60. Hardy J, Daly S, McQuade B, et al. A double-blind, randomised, parallel group, multinational, multicentre study comparing a single dose of ondansetron 24 mg p.o. with placebo and metoclopramide 10 mg t.d.s. p.o. in the treatment of opioid-induced nausea and emesis in cancer patients. Support Care Cancer. 2002;10(3):231-236.
61. Corli O, Cozzolino A, Battaiotto L. Effectiveness of levosulpiride versus metoclopramide for nausea and vomiting in advanced cancer patients: a double-blind, randomized, crossover study. J Pain Symptom Manage. 1995;10(7):521-526.
62. Kim SW, Shin IS, Kim JM, et al. Mirtazapine for severe gastroparesis unresponsive to conventional prokinetic treatment. Psychosomatics. 2006;47(5):440-442.
63. Koutsoumbi P, Epanomeritakis E, Tsiaoussis J, et al. The effect of erythromycin on human esophageal motility is mediated by serotonin receptors. Am J Gastroenterol. 2000;95(12):3388-3392.
64. Abrahamsson H. Treatment options for patients with severe gastroparesis. Gut. 2007;56(6):877-883.
65. Barone JA. Domperidone: a peripherally acting dopamine2-receptor antagonist. Ann Pharmacother. 1999;33(4):429-440.
66. Osborne RJ, Slevin ML, Hunter RW, Hamer J. Cardiotoxicity of intravenous domperidone. Lancet. 1985;2(8451):385.
67. Puisieux FL, Adamantidis MM, Dumotier BM, Dupuis BA. Cisaprideinduced prolongation of cardiac action potential and early after depolarizations in rabbit Purkinje fibres. Br J Pharmacol. 1996;117(7):1377-1379.
68. Enger C, Cali C, Walker AM. Serious ventricular arrhythmias among users of cisapride and other QT-prolonging agents in the United States. Pharmacoepidemiol Drug Saf. 2002;11(6):477-486.
69. Stacher G, Gaupmann G, Steinringer H, et al. Effects of cisapride on postcibal jejunal motor activity. Dig Dis Sci. 1989;34(9):1405-1410.
70. Twycross R, Wilcock A, Charlesworth S, Dickman A. Palliative care formulary. 2nd ed. Oxford, UK: Radcliffe Medical Press; 2002.
71. McCallum RW, Prakash C, Campoli-Richards DM, Goa KL. Cisapride. A preliminary review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use as a prokinetic agent in gastrointestinal motility disorders. Drugs. 1988;36(6):652-681.
72. Richelson E. Pharmacology of neuroleptics in use in the United States. J Clin Psychiatry. 1985;46(8 Pt 2):8-14.
73. Kudo S, Ishizaki T. Pharmacokinetics of haloperidol: an update. Clin Pharmacokinet. 1999;37(6):435-436.
74. Skinner J, Skinner A. Levomepromazine for nausea and vomiting in advanced cancer. Hosp Med. 1999;60(8):568-570.
75. Patt RB, Proper G, Reddy S. The neuroleptics as adjuvant analgesics. J Pain Symptom Manage. 1994;9(7):446-453.
76. Dahl SG. Pharmacokinetics of methotrimeprazine after single and multiple doses. Clin Pharmacol Ther. 1976;19(4):435-442.
77. Bymaster FP, Calligaro DO, Falcone JF, et al. Radioreceptor binding profile of the atypical antipsychotic olanzapine. Neuropsychopharmacology. 1996;14(2):87-96.
78. Callaghan JT, Bergstrom RF, Ptak LR, Beasley CM. Olanzapine: pharmacokinetic and pharmacodynamic profile. Clin Pharmacokinet. 1999;37(3):177-193.
79. Passik SD, Lundberg J, Kirsch KL, et al. A pilot exploration of the antiemetic activity of olanzapine for the relief of nausea in patients with advanced cancer and pain. J Pain Symp Manage. 2002;23(6):526-532.
80. Meltzer HY, Fibiger C. Olanzapine: a new atypical antipsychotic drug. Neuropsychopharmacology. 1996;14(2):83-85.
81. Bhana N, Foster RH, Olney R, Plosker GL. Olanzapine: an updated review of its use in the management of schizophrenia. Drugs. 2001;61(1):111-161.
82. Gralla RJ, Itri LM, Pisko SE, et al. Antiemetic efficacy of high-dose metoclopramide: randomized trials with placebo and prochlorperazine in patients with chemotherapy-induced nausea and vomiting. N Engl J Med. 1981;305(16):905-909.
83. Critchley P, Plach N, Grantham M, et al. Efficacy of haloperidol in the treatment of nausea and vomiting in the palliative patient: a systematic review. J Pain Symptom Manage. 2001;22(2):631-634.
84. Hardy JR, O'Shea A, White C, Gilshenan K, Welch L, Douglas C. The efficacy of haloperidol in the management of nausea and vomiting in patients with cancer. J Pain Symptom Manage. 2010;40(1):111-116.
85. Buttner M, Walder B, von Elm E, Tramer MR. Is low-dose haloperidol a useful antiemetic?: a meta-analysis of published and unpublished randomized trials. Anesthesiology. 2004;101(6):1454-1463.
86. Passik SD, Lundberg J, Kirsh KL, et al. A pilot exploration of the antiemetic activity of olanzapine for the relief of nausea in patients with advanced cancer and pain. J Pain Symptom Manage. 2002;23(6):526-532.
87. Twycross R, Bankby G, Hallowood J. The use of low-dose methotrimeprazine (levomepromazine) in the management of nausea and vomiting. Prog Palliat Care. 1997;5:49-53.
88. Mannix KA. Palliation of nausea and vomiting. In: Doyle D, Hanks G, Cherny NI, Calman K, editors. Oxford Textbook of Palliative Medicine. 3rd ed. Oxford, UK: Oxford University Press; 2004.
89. Wood CD, Cramer DB, Graybiel A. Antimotion sickness drug efficacy. Otolaryngol Head Neck Surg. 1981;89(6):1041-1044.
90. Twycross R, Wilcock A, Thorp S. PCF1. Palliative Care Formulary. London, UK: Radcliffe Medical Press; 1998.
91. Glare PA, Dunwoodie D, Clark K, et al. Treatment of nausea and vomiting in terminally ill cancer patients. Drugs. 2008;68(18):2575-2590.
92. Tan LB, Bryant S, Murray RG. Detrimental haemodynamic effects of cyclizine in heart failure. Lancet. 1988;1(8585):560-561.
93. Fick DM, Cooper JW, Wade WE, Waller JL, Maclean JR, Beers MH. Updating the Beers criteria for potentially inappropriate medication use in older adults: results of a US consensus panel of experts. Arch Intern Med. 2003;163(22):2716-2724.
94. Keeley PW. Nausea and vomiting in people with cancer and other chronic diseases. Clin Evid (Online). 2009;2009.
95. Gregory RE, Ettinger DS. 5-HT3 receptor antagonists for the prevention of chemotherapy-induced nausea and vomiting. A comparison of their pharmacology and clinical efficacy. Drugs. 1998;55(2):173-189.
96. Figg WD, Dukes GE, Pritchard JF, et al. Pharmacokinetics of ondansetron in patients with hepatic insufficiency. J Clin Pharmacol. 1996;36(3):206-215.
97. Gralla RJ, Osoba D, Kris MG, et al. Recommendations for the use of antiemetics: evidence-based, clinical practice guidelines. American Society of Clinical Oncology. J Clin Oncol. 1999;17(9):2971-2994.
98. Currow DC, Coughlan M, Fardell B, Cooney NJ. Use of ondansetron in palliative medicine. J Pain Symptom Manage. 1997;13(5):302-307.
99. Feuer DJ, Broadley KE. Corticosteroids for the resolution of malignant bowel obstruction in advanced gynaecological and gastrointestinal cancer. Cochrane Database Syst Rev. 2000;2:CD001219.
100. Czock D, Keller F, Rasche FM, Haussler U. Pharmacokinetics and pharmacodynamics of systemically administered glucocorticoids. Clin Pharmacokinet. 2005;44(1):61-98.
101. Ripamonti C, Twycross R, Baines M, et al. Clinical-practice recommendations for the management of bowel obstruction in patients with end-stage cancer. Support Care Cancer. 2001;9(4):223-233.
102. Maurer R, Gaehwiler BH, Buescher HH, Hill RC, Roemer D. Opiate antagonistic properties of an octapeptide somatostatin analog. Proc Natl Acad Sci U S A. 1982;79(15):4815-4817.
103. Martin BR, Wiley JL. Mechanism of action of cannabinoids: how it may lead to treatment of cachexia, emesis, and pain. J Supp Oncol. 2004;2(4):305-316.
104. Bagshaw SM, Hagen NA. Medical efficacy of cannabinoids and marijuana: a comprehensive review of the literature. J Palliat Care. 2002;18(2):111-122.
105. Walsh D, Nelson KA, Mahmoud FA. Established and potential therapeutic applications of cannabinoids in oncology. Support Care Cancer. 2003;11(3):137-143.
106. Beal JE, Olson R, Lefkowitz L, et al. Long-term efficacy and safety of dronabinol for acquired immunodeficiency syndrome-associated anorexia. J Pain Symptom Manage. 1997;14(1):7-14.
107. Rhodes VA, McDaniel RW. Nausea, vomiting, and retching: complex problems in palliative care. CA Cancer J Clin. 2001;51(4):232-248.
108. Bruera E, Strasser F, Palmer JL, et al. Effect of fish oil on appetite and other symptoms in patients with advanced cancer and anorexia/ cachexia: a double-blind, placebo-controlled study. J Clin Oncol. 2003;21(1):129-134.
109. Van Fleet S. Relaxation and imagery for symptom management: improving patient assessment and individualizing treatment. Oncol Nurs Forum. 2000;27(3):501-510.
110. Arakawa S. Relaxation to reduce nausea, vomiting, and anxiety induced by chemotherapy in Japanese patients. Cancer Nurs. 1997;20(5):342-349.
111. Molassiotis A. A pilot study of the use of progressive muscle relaxation training in the management of post-chemotherapy nausea and vomiting. Eur J Cancer Care (Engl). 2000;9(4):230-234.
112. Mundy EA, DuHamel KN, Montgomery GH. The efficacy of behavioral interventions for cancer treatment-related side effects. Semin Clin Neuropsychiatry. 2003;8(4):253-275.
113. Ahles TA, Tope DM, Pinkson B, et al. Massage therapy for patients undergoing autologous bone marrow transplantation. J Pain Symptom Manage. 1999;18(3):157-163.
114. Grealish L, Lomasney A, Whiteman B. Foot massage. A nursing intervention to modify the distressing symptoms of pain and nausea in patients hospitalized with cancer. Cancer Nurs. 2000;23(3):237-243.
115. Pan CX, Morrison RS, Ness J, Fugh-Berman A, Leipzig RM. Complementary and alternative medicine in the management of pain, dyspnea, and nausea and vomiting near the end of life. A systematic review. J Pain Symptom Manage. 2000;20(5):374-387.
116. Hickok JT, Roscoe JA, Morrow GR, Ryan JL. A Phase II/III randomized, placebo-controlled, double-blind clinical trial of ginger (Zingiber officinale) for nausea caused by chemotherapy for cancer: a currently accruing URCC CCOP Cancer Control Study. Support Cancer Ther. 2007;4(4):247-250.
117. Storey PS. Obstruction of the GI tract. Am J Hosp Palliat Care. 1991;8(3):5.
118. Pothuri B, Meyer L, Gerardi M, Barakat RR, Chi DS. Reoperation for palliation of recurrent malignant bowel obstruction in ovarian carcinoma. Gynecol Oncol. 2004;95(1):193-195.
119. Pothuri B, Montemarano M, Gerardi M, et al. Percutaneous endoscopic gastrostomy tube placement in patients with malignant bowel obstruction due to ovarian carcinoma. Gynecol Oncol. 2005;96(2):330-334.
120. Cunningham MJ, Bromberg C, Kredentser DC, Collins MB, Malfetano JH. Percutaneous gastrostomy for decompression in patients with advanced gynecologic malignancies. Gynecol Oncol. 1995;59(2):273-276.
121. Campagnutta E, Cannizzaro R, Gallo A, et al. Palliative treatment of upper intestinal obstruction by gynecological malignancy: the usefulness of percutaneous endoscopic gastrostomy. Gynecol Oncol. 1996;62(1):103-105.
122. Herman LL, Hoskins WJ, Shike M. Percutaneous endoscopic gastrostomy for decompression of the stomach and small bowel. Gastrointest Endosc. 1992;38(3):314-318.
123. Campagnutta E, Cannizzaro R. Percutaneous endoscopic gastrostomy (PEG) in palliative treatment of non-operable intestinal obstruction due to gynecologic cancer: a review. Eur J Gynaecol Oncol. 2000;21(4):397-402.
124. Guitron A, Adalid R, Huerta F, Macias M, Sanchez-Navarrete M. Palliative treatment of esophageal cancer with transendoscopic injection of alcohol. Rev Gastroenterol Mex. 1996;61(3):208-211. Spanish.
125. Nwokolo CU, Payne-James JJ, Silk DB, Misiewicz JJ, Loft DE. Palliation of malignant dysphagia by ethanol induced tumour necrosis. Gut. 1994;35(3):299-303.
126. Ahlquist DA, Gostout CJ, Viggiano TR, et al. Endoscopic laser palliation of malignant dysphagia: a prospective study. Mayo Clin Proc. 1987;62(10):867-874.
127. Brennan FN, McCarthy JH, Laurence BH. Endoscopic Nd-YAG laser therapy for palliation of upper gastrointestinal malignancy. Med J Aust. 1990;153(1):27-31.
128. Dallal HJ, Smith GD, Grieve DC, Ghosh S, Penman ID, Palmer KR. A randomized trial of thermal ablative therapy versus expandable metal stents in the palliative treatment of patients with esophageal carcinoma. Gastrointest Endosc. 2001;54(5):549-557.
129. Costamagna G, Shah SK, Tringali A, Mutignani M, Perri V, Riccioni ME. Prospective evaluation of a new self-expanding plastic stent for inoperable esophageal strictures. Surg Endosc. 2003;17(6):891-895.
130. Dormann AJ, Eisendrath P, Wigginghaus B, Huchzermeyer H, Deviere J. Palliation of esophageal carcinoma with a new self-expanding plastic stent. Endoscopy. 2003;35(3):207-211.
131. Decker P, Lippler J, Decker D, Hirner A. Use of the Polyflex stent in the palliative therapy of esophageal carcinoma: results in 14 cases and review of the literature. Surg Endosc. 2001;15(12):144-147.
132. De Palma GD, di Matteo E, Romano G, Fimmano A, Rondinone G, Catanzano C. Plastic prosthesis versus expandable metal stents for palliation of inoperable esophageal thoracic carcinoma: a controlled prospective study. Gastrointest Endosc. 1996;43(5):478-482.
133. Mosca F, Consoli A, Stracqualursi A, Persi A, Lipari G, Portale TR. Our experience with the use of a plastic prosthesis and self-expanding stents in the palliative treatment of malignant neoplastic stenoses of the esophagus and cardia. Comparative analysis of results. Chir Ital. 2002;54(3):341-350. Italian.
134. Knyrim K, Wagner HJ, Bethge N, Keymling M, Vakil N. A controlled trial of an expansile metal stent for palliation of esophageal obstruction due to inoperable cancer. N Engl J Med. 1993;329(18):1302-1307.
135. Mosca F, Consoli A, Stracqualursi A, Persi A, Portale TR. Comparative retrospective study on the use of plastic prostheses and self-expanding metal stents in the palliative treatment of malignant strictures of the esophagus and cardia. Dis Esophagus. 2003;16(2):119-125.
136. Shimi SM. Self-expanding metallic stents in the management of advanced esophageal cancer: review. Semin Laparosc Surg. 2000;7(1):9-21.
137. Dormann A, Meisner S, Verin N, Wenk Lang A. Self-expanding metal stents for gastroduodenal malignancies: systematic review of their clinical effectiveness. Endoscopy. 2004;36(6):543-550.
138. Lelcuk S, Merhav A, Klausner JM, Gutman M, Greif F, Rozin R. Rectoscopic decompression of acute recto-sigmoid obstruction. Endoscopy. 1987;19(5):209-210.
139. Xinopoulos D, Dimitroulopoulos D, Theodosopoulos T, et al. Stenting or stoma creation for patients with inoperable malignant colonic obstructions? Results of a study and cost-effectiveness analysis. Surg Endosc. 2004;18(3):421-426.
140. Carne PW, Frye JN, Robertson GM, Frizelle FA. Stents or open operation for palliation of colorectal cancer: a retrospective, cohort study of perioperative outcome and long-term survival. Dis Colon Rectum. 2004;47(9):1455-1461.
141. Kimberly Moore Dalal, Marc J. Gollub, Thomas J. Miner, et al. Management of patients with malignant bowel obstruction and stage IV colorectal cancer. Journal of Palliative Medicine. 2011;14(7):822-828.
142. Woodruff R. Palliative medicine: evidence-based symptomatic and supportive care for patients with advanced cancer. 4th ed. Melbourne, Australia: Oxford University Press; 2004.
143. Dahl SG, Strandjord RE. Pharmacokinetics of chlorpromazine after single and chronic dosage. Clin Pharmacol Ther. 1977;21(4):437-448.
144. Griffin DS, Baselt RC. Blood and urine concentrations of cyclizine by nitrogen-phosphorus gas-liquid chromatography. J Anal Toxicol. 1984;8(2):97-99.
145. Heykants J, Hendriks R, Meuldermans W, Michiels M, Scheygrond H, Reyntjens H. On the pharmacokinetics of domperidone in animals and man. IV. The pharmacokinetics of intravenous domperidone and its bioavailability in man following intramuscular, oral and rectal administration. Eur J Drug Metab Pharmacokinet. 1981;6(1):61-70.
146. Huang YC, Colaizzi JL, Bierman RH, Woestenborghs R, Heykants JJ. Pharmacokinetics and dose proportionality of domperidone in healthy volunteers. J Clin Pharmacol. 1986;26(8):628-632.
147. Ebert U, Siepmann M, Oertel R, Wesnes KA, Kirch W. Pharmacokinetics and pharmacodynamics of scopolamine after subcutaneous administration. J Clin Pharmacol. 1998;38(8):720-726.
148. Bateman DN. Clinical pharmacokinetics of metoclopramide. Clin Pharmacokinet. 1983;8(6):523-529.
149. Kutz K, Nuesch E, Rosenthaler J. Pharmacokinetics of SMS201-995 in healthy subjects. Scand J Gastroenterol Suppl. 1986;119:65-72.
150. Chanson P, Timsit J, Harris AG. Clinical pharmacokinetics of octreotide. Therapeutic applications in patients with pituitary tumours. Clin Pharmacokinet. 1993;25(5):375-391.
151. Callaghan JT, Bergstrom RF, Ptak LR, Beasley CM. Olanzapine. Pharmacokinetic and pharmacodynamic profile. Clin Pharmacokinet. 1999;37(3):177-193.
152. Isah AO, Rawlins MD, Bateman DN. Clinical pharmacology of prochlorperazine in healthy young males. Br J Clin Pharmacol. 1991;32(6):677-684.
153. Taylor WB, Bateman DN. Preliminary studies of the pharmacokinetics and pharmacodynamics of prochlorperazine in healthy volunteers. Br J Clin Pharmacol. 1987;23(2):137-142.
154. Taylor G, Houston JB, Shaffer J, Mawer G. Pharmacokinetics of promethazine and its sulphoxide metabolite after intravenous and oral administration to man. Br J Clin Pharmacol. 1983;15(3):287-293.
155. Paton DM, Webster DR. Clinical pharmacokinetics of H1-receptor antagonists (the antihistamines). Clin Pharmacokinet. 1985;10(6):477-497.
156. Dimmit DC, Choo YS, Martin LA, Arumugham T, Hahane WF, Weir SJ. Intravenous pharmacokinetics and absolute oral bioavailability of dolasetron in healthy volunteers: part 1. Biopharm Drug Dispos. 1999;20(1):29-39.
157. Lerman J, Sims C, Sikich N, et al. Pharmacokinetics of the active metabolite (MDL 74,156) of dolasetron mesylate after oral or intravenous administration to anesthetized children. Clin Pharmacol Ther. 1996;60(5):485-492.
158. Plosker GL, Goa KL. Granisetron. A review of its pharmacological properties and therapeutic use as an antiemetic. Drugs. 1991;42(5):805-824.
159. Roila F, Del Favero A. Ondansetron clinical pharmacokinetics. Clin Pharmacokinet. 1995;29(2):95-109.
160. Simpson KH, Hicks FM. Clinical pharmacokinetics of ondansetron. A review. J Pharm Pharmacol. 1996;48(8):774-781.
161. Wilde MI, Markham A. Ondansetron. A review of its pharmacology and preliminary clinical findings in novel applications. Drugs. 1996;52(5):773-794.
162. Stoltz R, Cyong JC, Shah A, Parisi S. Pharmacokinetic and safety evaluation of palonosetron, a 5-hydroxytryptamine-3 receptor antagonist, in US and Japanese healthy subjects. J Clin Pharmacol. 2004;44(5):520-531.
163. Hunt TL, Gallagher SC, Cullen MT Jr, Shah AK. Evaluation of safety and pharmacokinetics of consecutive multiple-day dosing of palonosetron in healthy subjects. J Clin Pharmacol. 2005;45(5):589-596.
164. de Bruijn KM. Tropisetron. A review of the clinical experience. Drugs. 1992;43(Suppl 3):11-22.
165. Lee CR, Plosker GL, McTavish D. Tropisetron. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential as an antiemetic. Drugs. 1993;46(5):925-943.